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Objective: To provide an evidence-based guide for the MRI interpretation of complete tumor response after neoadjuvant 
chemoradiation therapy (CRT) for rectal cancer using visual assessment on T2-weighted imaging (T2) and diffusion-weighted 
imaging (DWI).
Materials and Methods: PubMed MEDLINE, EMBASE, and Cochrane Library were searched on November 28, 2019 to identify 
articles on the following issues: 1) sensitivity and specificity of T2 or DWI for diagnosing pathologic complete response (pCR) 
and the criteria for MRI diagnosis; 2) MRI alone vs. MRI combined with other test(s) in sensitivity and specificity for pCR; 
and 3) tests to select patients for the watch-and-wait management. Eligible articles were selected according to meticulous 
criteria and were synthesized.
Results: Of 1615 article candidates, 55 eligible articles (for all three issues combined) were identified. Combined T2 and 
DWI performed better than T2 alone, with a meta-analytic summary sensitivity of 0.62 (95% confidence interval [CI], 0.43–
0.77; I2 = 80.60) and summary specificity of 0.89 (95% CI, 0.80–0.94; I2 = 92.61) for diagnosing pCR. The criteria for the 
complete response on T2 in most studies had the commonality of remarkable tumor decrease to the absence of mass-like or 
nodular intermediate signal, although somewhat varied, as follows: (near) normalization of the wall; regular, thin, hypointense 
scar in the luminal side with (near) normal-appearance or homogeneous intermediate signal in the underlying wall; and 
hypointense thickening of the wall. The criteria on DWI were the absence of a hyperintense signal at high b-value (≥ 800 
sec/mm2) in most studies. The specific algorithm to combine T2 and DWI was obscure in half of the studies. MRI combined 
with endoscopy was the most utilized means to select patients for the watch-and-wait management despite a lack of strong 
evidence to guide and support a multi-test approach.
Conclusion: This systematic review and meta-analysis provide an evidence-based practical guide for MRI assessment of 
complete tumor response after CRT for rectal cancer.
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PubMed MEDLINE, EMBASE, and Cochrane Library were 
searched to identify articles related to any of the three 
issues as follows:
• Issue 1: sensitivity and specificity of MRI (T2 or DWI) 
for diagnosing pCR and the criteria for the MRI diagnosis
• Issue 2: comparison of MRI alone (T2 with or without 
DWI) and MRI combined with other test(s) regarding 
sensitivity and specificity for pCR
• Issue 3: tests used to select patients for the watch-and-
wait management.
This study developed the search queries according to the 
PICO method (18) as much as applicable and jointly used 
hand-searching to enable an exhaustive literature search, 
as shown in Table 1. Besides the basic search terms, this 
study also included extra terms that frequently appeared in 
the relevant articles in the search query in ‘OR’ combination 
to expand the search (i.e., additional terms regarding P, I, 
and C as shown in Table 1). The last update of the literature 
database search was on November 28, 2019. The literature 
database search covered both print publications and 
electronic publications ahead of print. 
A total of 1615 articles were screened for eligibility, after 
deleting overlaps between the three databases (Fig. 1). 
The general criteria for article exclusion were as follows: 1) 
duplicated publications; 2) articles not within the topics of 
interest of this study; 3) not an original research or study 
protocol (for issue 3), such as case reports, review articles, 
editorials, letters, or comments; 4) articles without the full 
text available, such as conference abstract/proceedings; 
and 5) articles written in other languages than English. 
Articles that had any of these characteristics were excluded. 
Then, each issue-specific eligibility criteria were applied 
to further select relevant articles, as explained later in the 
corresponding sections. The article screening and selection 
were performed by one of eight authors. In any case, where 
there was an ambiguity, another reviewer was invited to 
jointly review the article and arrive at a consensus. The 
nine authors also performed data extraction from eligible 
articles for meta-analysis and systematic review in the same 
manner, i.e., data extraction by one of the eight authors 
and double-checked by the remaining author to make a 
INTRODUCTION
Preoperative neoadjuvant chemoradiation therapy (CRT) 
is now a standard treatment for rectal cancers with a high 
risk of recurrence after surgery (1). CRT typically takes 
5–6 weeks (long-course therapy), and surgery is generally 
performed a few months later (1). Within the published 
literature, 10–25% of patients achieve pathologic complete 
response (pCR) after CRT, i.e., no residual tumor on 
pathologic examination (1, 2). Evidence from observational 
studies suggests that patients who are considered to have 
achieved pCR after CRT could be managed with careful 
regular surveillance, referred to as the watch-and-wait 
approach as an alternative to surgery (3-7). This watch-
and-wait approach may provide an opportunity to avoid 
surgical complications, perioperative morbidity and 
mortality, and the need for a permanent stoma. It is critical 
to carefully determine patients with no clinically apparent 
residual tumor with a thorough assessment of the treatment 
response to CRT, as the safety of the watch-and-wait 
approach is yet uncertain.
Magnetic resonance imaging (MRI) is the imaging of 
choice in patients with rectal cancer to evaluate the 
response to CRT, as well as for the initial pretreatment 
evaluation (7-9). Unlike well-established guidelines on the 
pretreatment MRI evaluation of rectal cancers (10-15), there 
is a relative scarcity of guidance for the MRI evaluation 
of CRT response. Therefore, this study aimed to provide an 
evidence-based guide from the Korean Society of Abdominal 
Radiology (KSAR) for the MRI assessment of complete tumor 
response after CRT for rectal cancer. There is a variety of 
MRI techniques used for this purpose. Of those, this study 
addresses visual assessment using T2-weighted imaging (T2) 
and diffusion-weighted imaging (DWI) because these are 
the imaging methods that are widely used in the real-world 
practice at present. Other techniques—including radiomics, 
texture analysis, modeling using artificial intelligence (such 
as machine learning or deep learning), quantitative lesion 
metrics (such as volumetry or sum of the areas by drawing 
the lesion boundary), quantitative diffusion analysis (such 
as apparent diffusion coefficient, kurtosis coefficient, and 
intravoxel incoherent motion parameters), and perfusion 
analysis by dynamic-contrast enhanced imaging—were not 
considered as these are mostly still in research territory 
due to limitations in generalizability, reproducibility, and 
practicality (16, 17). Additionally, this study focuses on the 




Table 1. Query for Literature Database Search
PICO
Query for Issues 1 and 2 Query for Issue 3
Search Concept Search Term Search Concept Search Term
P: A AND B  
  AND C
A.  Patient with  
rectal cancer:  
#1 OR #2
#1: “Rectal Neoplasms”[Mesh] A.  Patient with  
rectal cancer:  
#1 OR #2
#1: “Rectal Neoplasms”[Mesh]
#2:  (Colorectal[TW] OR Rectal[TW] OR rectum[TW]  
OR Anus[TW]) AND (Neoplasm*[TW] OR 
neoplasia[TW] OR cancer*[TW] OR tumor*[TW] 
OR tumour*[TW] OR Carcinoma*[TW] OR 
Malignan*[TW])
#2:  (Colorectal[TW] OR Rectal[TW] OR 
rectum[TW] OR Anus[TW]) AND 
(Neoplasm*[TW] OR neoplasia[TW] 
OR cancer*[TW] OR tumor*[TW] OR 
tumour*[TW] OR Carcinoma*[TW] 
OR Malignan*[TW])
B.  Undergoing  
chemoradiation 
therapy: #3  
OR #4 OR #5  
OR #6
#3: “Chemoradiotherapy”[Mesh] B.  Undergoing  
chemoradiation 
therapy: #3  
OR #4 OR #5  
OR #6
#3: “Chemoradiotherapy”[Mesh]
#4:  chemoradiotherap*[TW] OR 
chemoradiation*[TW] OR 
radiochemotherap*[TW] OR chemo-rad*[TW] 
OR Radio-Chemo*[TW] OR “CCRT”[TW] OR 
“CCRTx”[TW]
#4:  chemoradiotherap*[TW] OR 
chemoradiation*[TW] OR 
radiochemotherap*[TW] OR  
chemo-rad*[TW] OR Radio-
Chemo*[TW] OR “CCRT”[TW] OR 
“CCRTx”[TW]
#5:  chemotherap*[TW] AND (radiation therap*[TW] 
OR Radiotherap*[TW])
#5:  chemotherap*[TW] AND (radiation 
therap*[TW] OR Radiotherap*[TW])
#6:  “Neoadjuvant Therapy”[Mesh] OR 
neoadjuvant*[TW]
#6:  “Neoadjuvant Therapy”[Mesh] OR 
neoadjuvant*[TW]





#7:  Basic terms: complete respon*[TW] OR  
complete remission*[TW]
C.  Managed by  
watch and wait  
approach after  
therapy: #14
#14:  “Watchful Waiting”[Mesh] OR 
“Watch and wait”[TW] OR  
“Wait-and-see”[TW] OR  
“Watch & Wait”[TW]
#8:  Additional terms to expand the search: 
completed respon*[TW] OR pathologic 
respon*[TW] OR Clinical respon*[TW] OR 
“tumour regression grade”[TW] OR “tumor 
regression grade”[TW] OR “tumour regression 
grades”[TW] OR “tumor regression grades”[TW] 
OR viable[TW]
I and C MRI or other  
   typical tests 
(endoscopy, 
endorectal 
ultrasound, CT,  
or PET): #9 OR  
#10 OR #11 OR  
#12 OR #13
#9:  Basic terms: Magnetic Resonance  
Imaging[Mesh] OR Magnetic Resonanc*[TW] OR 
MRI[TW] OR MRIs[TW] OR MR[TW] 
Not applicable
#10:  Additional terms to expand the search: 
“diffusion-weighted”[TW] OR “DWI”[TW] OR 
“T2-weighted”[TW]
#11:  “Colonoscopy”[Mesh] OR colonoscop*[TW] 
OR Endoscop*[TW] OR Ultrasound*[TW] 
OR ultrasonograp*[TW] OR EUS[TW] OR 
Endosonography[Mesh] OR Endosonograp*[TW]
#12:  “Tomography, X-Ray Computed”[Mesh] 
OR CT[TI] OR Computed tomograp*[TW] 
OR computer assisted tomograp*[TW] OR 
computerised tomograp*[TW]
#13:  “Positron-Emission Tomography”[Mesh] OR 
“Positron-Emission”[TW] OR PET[TW]
O Not applied, i.e., hand search of relevant articles Not applicable
Others Written in English #15: English[Lang]  Written in English #15: English[Lang]  
Final search  
  query
P AND (I and C) AND Others P AND Others
Table shows search query for PubMed MEDLINE. Search in EMBASE and Cochrane Library was performed using same search queries except 
for minor modifications related to differences in design of three databases. We additionally limited EMBASE search to article, article in 
press, and review by adding “AND (‘article’/it OR ‘article in press’/it OR ‘review’/it)” to query for more effective search as EMBASE includes 
a lot more conference abstracts/proceedings than PubMed MEDLINE. We could not use language restriction to English (#15) for Cochrane 
Library as it did not have this functionality. CT = computed tomography, PET = positron-emission tomography
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because ROC analysis alone, unaccompanied by a suggestion 
of a specific cutoff, can only show a theoretical diagnostic 
performance over the entire range of possible cutoff 
values. Therefore, it cannot be directly translated into daily 
practice. 
Meta-Analysis of the Sensitivity and Specificity of T2, 
DWI, and Combined T2 and DWI for Diagnosing pCR
One article may contain more than one set of the 2-by-
2 results (Fig. 2). Then, the data for meta-analysis were 
chosen as follows: the main result was considered when 
both the main result for the entire subjects and result(s) 
for the subgroup(s) were present; if one article presents 
parallel results for > 1 independent patient groups, each 
was considered as a separate study; and in case of a multi-
reader study or a study suggesting > 1 discrete diagnostic 
consensus for any ambiguities. All the nine people who 
participated in the literature review were board-certified 
radiologists with expertise in the subject matters as well as 
in the systematic review of the literature.
Issue 1: Sensitivity and Specificity of MRI (T2 or 
DWI) for Diagnosing pCR and the Criteria for the MRI 
Diagnosis
For this analysis, eligible articles were selected by 
further applying the following issue-specific criteria: 
1) accurate, sufficient details to construct a diagnostic 
2-by-2 table of visual interpretation of T2 or DWI and 
the reference standard findings for pCR (Fig. 2); 2) at 
least ten patients for both patients with pCR and those 
without pCR; 3) technical requirement for MRI according 
to the 2016 recommendation from the European Society 
of Gastrointestinal and Abdominal Radiology (ESGAR), 
including use of an external surface coil on a 1.5T or 3T 
systems and, in case of DWI, use of a high b-value of ≥ 800 
sec/mm2 (16); and 4) MRI obtained after the completion 
of CRT. Articles not fulfilling any of these criteria were 
excluded. As shown in Figure 2, pCR instead of residual 
cancer was considered as the target condition to diagnose, 
and the sensitivity and specificity were defined accordingly. 
Studies that reported receiver operating characteristic (ROC) 
analysis alone without presenting any specific cutoff to use 
for the binary diagnosis were excluded. The exclusion was 
Fig. 1. Flow diagram of literature search. Four articles selected for issue 2 (asterisk) are also included in 23 articles selected for issue 1. 
DWI = diffusion-weighted imaging, MRI = magnetic resonance imaging, pCR = pathologic complete response, T2 = T2-weighted imaging
Records identified through database searching
PubMed MEDLINE (n = 1152), EMBASE (n = 939), Cochrane (n = 272)










Issue 2: original research
of MRI alone vs. combined
MRI and other test(s) in
accuracy for diagnosing pCR
(n = 4*)
Issue 1: original research
of MRI (T2 or DWI)
accuracy for diagnosing pCR
(n = 23)
Issue 3: original research









complete response a c
Index test:
not complete response b d
Sensitivity for pCR = a / (a + b)
Specificity for pCR = d / (c + d)




criterion, the result of the reader or the diagnostic criterion 
that yielded the highest Youden index value was considered.
The presence of heterogeneity between studies 
concerning sensitivity and specificity was assessed using 
Higgins I2 statistics (19, 20). Heterogeneity by threshold 
effect was analyzed primarily by visual assessment of the 
coupled forest plots of sensitivity and specificity. It was 
further tested using the Spearman correlation coefficient 
between sensitivity and 1-specificity (20, 21). The summary 
sensitivity and specificity and their 95% confidence 
intervals (CIs) were obtained using a bivariate random-
effects model (20, 22). These analyses were performed 
separately for T2, DWI, and combined T2 and DWI.
Of the eligible studies, a subgroup of studies that 
reported sensitivity and specificity for pCR both for T2 and 
for combined T2 and DWI in the same group of patients 
were identified. T2 and combined T2 and DWI were 
compared regarding the sensitivity and specificity for pCR 
in this subgroup of studies using a joint-model bivariate 
meta-regression. 
The statistical analyses were conducted using Stata 
version 15.1 (StataCorp LLC, College Station, TX, USA), with 
p < 0.05 considered statistically significant.
Systematic Review of the Criteria for the MRI Diagnosis of 
Complete Tumor Response
The criteria for diagnosing complete tumor response on 
either T2 or DWI described in the studies identified were 
categorized, and the number of articles for each category 
was counted. The methods of combining the results of the 
two imaging methods were recorded for studies reporting 
the sensitivity and specificity of combined T2 and DWI.
Issue 2: Comparison of MRI alone (T2 with or without 
DWI) and MRI Combined with Other Test(s) Regarding 
Sensitivity and Specificity for pCR
We considered endoscopy, endorectal ultrasound, and 
positron-emission tomography (PET, including PET, PET-
CT, and PET-MR) as other tests used in combination with 
MRI. Reports of studies that evaluated the sensitivity and 
specificity for diagnosing pCR both for MRI alone and for 
MRI combined with any of these other tests in the same 
group of patients were identified. Otherwise, the article 
selection criteria were the same as those explained earlier 
in issue 1. MRI alone and MRI combined with other test(s) 
were compared regarding sensitivity and specificity for pCR 
using a joint-model bivariate meta-regression. Stata version 
15.1 was used, with p < 0.05 considered statistically 
significant.
Issue 3: Tests Used to Select Patients for the Watch-and-
Wait Management
Articles that collected patients to offer the watch-and-
wait management after CRT for rectal cancer and mentioned 
the use of specific test(s) for the patient selection, for 
example, a clear mention of MRI, endoscopy, etc., instead of 
a vague description of “various imaging modalities,” besides 
basic physician assessment and physical examination (such 
as digital rectal examination), were collected. Both original 
research studies and research protocols describing a plan 
for such a study were identified. The two types of articles 
were checked regarding any overlap, i.e., a publication 
of research that corresponds to a previously published 
protocol. Specific tests that were used to select patients 
for the watch-and-wait management, as described in the 
published articles, were summarized.
RESULTS
Article Selection
The article screening and selection processes are 
summarized in Figure 1. A total of 23 articles (23-45) 
were identified regarding issues 1 and 2, and a total of 32 
articles were identified for issue 3 (6, 46-76).
Issue 1: Sensitivity and Specificity of MRI (T2 or 
DWI) for Diagnosing pCR and the Criteria for the MRI 
Diagnosis
Of the 23 eligible articles (23-45), 20 were reports of 
retrospective research studies, and three were prospective 
studies. They included a total of 40–514 patients (median, 
103 patients); with 10–103 patients with pCR (median, 
21 patients) and 29–411 patients (median, 83 patients) 
without pCR (i.e., residual tumor). There were 17 studies, 
five studies (a study by Cai et al. (25) was counted twice as 
it had separate results for two independent patient groups, 
each of which was considered separately for the meta-
analysis), and eight studies that reported the sensitivity 
and specificity for diagnosing pCR for T2, DWI, and 
combined T2 and DWI, respectively.
Meta-Analysis of the Sensitivity and Specificity of T2, 
DWI, and Combined T2 and DWI for Diagnosing pCR
The meta-analytic results of the 17 studies reporting the 
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p = 0.056). The summary sensitivity and specificity were 
0.49 (95% CI, 0.33–0.65) and 0.86 (95% CI, 0.74–0.93), 
respectively.
The meta-analytic results of the five studies reporting the 
sensitivity and specificity of DWI for diagnosing pCR (25, 
28, 39, 41) are summarized in Figure 3B as coupled forest 
plots. There was a large study heterogeneity both for the 
sensitivity and the specificity (I2 = 80.96 [95% CI, 64.84–
97.09] for sensitivity and I2 = 82.38 [95% CI, 67.73–97.03] 
sensitivity and specificity of T2 for diagnosing pCR (23, 
24, 27-34, 38-40, 42-45) are summarized in Figure 3A as 
coupled forest plots. There was a large study heterogeneity 
both for the sensitivity and the specificity (I2 = 90.82 
[95% CI, 87.54–94.10] for sensitivity and I2 = 97.51 [95% 
CI, 96.91–98.10] for specificity). The coupled forest plots 
revealed a mild inverse relationship between sensitivity and 
specificity, although the Spearman’s rho between sensitivity 






















Q = 21.01, df = 4.00, p < 0.01








Q = 22.70, df = 4.00, p < 0.01






























































Q = 174.25, df = 16.00, p < 0.01




















Q = 641.85, df = 16.00, p < 0.01
I2 = 97.51 (96.91–98.10)
Fig. 3. Coupled forest plots of sensitivity and specificity of MRI for diagnosing pCR.
A. T2. B. DWI. Cai (2014) (25) is included twice as it contains separate results for two independent patient groups, each of which was considered 








for specificity). The threshold effect was not apparent 
(Spearman’s rho between sensitivity and 1-specificity = 
-0.600, p = 0.285). The summary sensitivity and specificity 
were 0.86 (95% CI, 0.63–0.96) and 0.80 (95% CI, 0.69–
0.88), respectively.
The meta-analytic results of the eight studies reporting 
the sensitivity and specificity of combined T2 and DWI for 
diagnosing pCR (26, 28, 31, 34-37, 40) are summarized in 
Figure 3C as coupled forest plots. There was a large study 
heterogeneity both for the sensitivity and the specificity 
(I2 = 80.60 [95% CI, 67.85–93.35] for sensitivity and I2 = 
92.61 [95% CI, 88.90–96.32] for specificity). The threshold 
effect was not apparent (Spearman’s rho between sensitivity 
and 1-specificity = 0.333, p = 0.420). The summary 
sensitivity and specificity were 0.62 (95% CI, 0.43–0.77) 
and 0.89 (95% CI, 0.80–0.94), respectively.
Four studies reported the sensitivity and specificity for 
pCR both for T2 and for combined T2 and DWI in the same 
group of patients (28, 31, 34, 40). The details are provided 
in Table 2. None of the individual studies explicitly reported 
statistical comparisons regarding sensitivity and specificity 
between T2 and combined T2 and DWI. The meta-analytic 
comparison revealed a significant difference between the 
two imaging techniques (p = 0.01). According to the sample 
values alone reported in the individual studies (i.e., without 
regard to statistical comparison), three studies reported an 
increase in both sensitivity and specificity with combined 
T2 and DWI compared with T2 alone (31, 34, 40). 
Systematic Review of the Criteria for the MRI Diagnosis of 
Complete Tumor Response
The criteria for diagnosing complete tumor response on 
either T2 or DWI and the methods of combining the results 
of T2 and DWI, as reported in the 23 eligible articles (23-
45), are summarized in Table 3. For the T2, most studies 
used the absence of visible tumor signal as the criteria. 
Meanwhile, the exact definitions and strictness for the 
absence of visible tumor varied among studies, ranging 
from complete normalization to hypointense thickening 
(i.e., dense fibrosis) of the wall in the tumor bed. For DWI, 
most articles adopted the absence of a hyperintense signal 
on high b-value (≥ 800 sec/mm2) DWI in the former tumor 
location. The methods of combining the results of T2 and 
DWI were obscure in half of the studies. Those studies 
that specifically reported the rules to combine T2 and DWI 
considered the absence of residual tumor on both T2 and 
DWI as complete tumor response or primarily followed 
T2 findings and referred to DWI when T2 findings were 
equivocal.
Issue 2: Comparison of MRI Alone (T2 with or without 
DWI) and MRI Combined with Other Test(s) Regarding 
Sensitivity and Specificity for pCR
Four studies reported the sensitivity and specificity for pCR 
both for MRI alone and for MRI combined with other test(s) 
in the same group of patients (32, 33, 36, 37). The details 
are provided in Table 4. The meta-analytic comparison 
revealed a significant difference between MRI alone and 
MRI combined with other test(s) (p = 0.02). According to 































Q = 36.08, df = 7.00, p < 0.01











Q = 94.73, df = 7.00, p < 0.01
I2 = 92.61 (88.90–96.32)
Fig. 3. Coupled forest plots of sensitivity and specificity of MRI for diagnosing pCR.






Complete Response on MRI after CRT for Rectal Cancer
https://doi.org/10.3348/kjr.2020.0483kjronline.org
DISCUSSION: KSAR GUIDE
Sensitivity and Specificity of MRI for Diagnosing pCR
There is a limitation in interpreting the meta-analytic 
summary sensitivity and specificity of T2 or DWI for 
diagnosing pCR due to the large heterogeneity in the 
published results. Study heterogeneity is common for 
systematic review and meta-analysis of diagnostic test 
accuracy (77). Determining the specific causes for the 
heterogeneity is difficult because, in general, various 
factors are intertwined. Within the limitations, MRI using 
visual assessment of T2 overall had low sensitivity and 
moderately high specificity for diagnosing pCR after CRT 
for rectal cancer. Adding DWI to T2 seems beneficial as it 
increased the diagnostic performance to some extent.
three studies showed higher specificity but lower sensitivity 
for pCR when MRI was combined with other test(s) (32, 
33, 36), whereas one study reported an increase in both 
sensitivity and specificity when endoscopy and digital rectal 
examination were also used combined with MRI (37). 
Issue 3: Tests Used to Select Patients for the Watch-and-
Wait Management
Twenty-nine original research articles (6, 48-65, 67-76) 
and three reports of research protocols (46, 47, 66) were 
eligible. There was no overlap between them. The details 
are summarized in Table 5. Almost all studies adopted MRI 
and endoscopy as the tests to select patients for the watch-
and-wait management despite some small variations among 
studies.


















Significantly higher overall  
   accuracy for combined T2  
and DWI compared with T2  
(p = 0.0313 by McNemar test)
T2 findings as primary results,  
   with DWI to override T2 when 
T2 findings are equivocal or to 
increase reader confidence if T2 
and DWI findings are consistent
Combined T2  











No statistical comparisons  
   regarding binary 
interpretations. Area under 
ROC curve was 0.8 for 
combined T2 and DWI and 
0.76 for T2 (p = 0.39)
Obscure
Combined T2  











No statistical comparisons  
   regarding binary 
interpretations. Area under 
ROC curve was 0.89 for 
combined T2 and DWI and 
0.77 for T2 (p = 0.005)
Obscure
Combined T2  











No statistical comparisons Obscure†
Combined T2  













p = 0.01 from joint-model  
   bivariate meta-regression 
analysis
NA
Combined T2  







*Numbers in parentheses are number of patients unless specified otherwise, †Article states complete tumor response on MRI when both 
T2 and DWI were negative for residual tumor. However, reported results are more compatible with combined MRI result of complete tumor 
response when T2 or DWI was negative for residual tumor. CI = confidence interval, DWI = diffusion-weighted imaging, MR = magnetic 




The diagnostic performance of MRI was moderate despite 
the combined use of T2 and DWI, and the lack of visible 
residual tumor on these imaging examinations does not 
necessarily mean pCR. This is primarily because of the 
pathologic nature of the tumor response to CRT (Fig. 4) 
(78). Rectal cancer is known to respond to CRT through 
fragmentation and shrinkage (78). Besides, a small minority 
of originally non-mucinous rectal cancers may develop 
mucin lakes (8, 78). This mucinous transformation is 
considered a good prognostic sign, like fibrosis, and should 
be distinguished from the primarily mucinous subtype that 
tends to show a poor response to CRT (8). Fragmentation, 
i.e., the destruction of the main tumor mass and formation 
of small nests of tumor cells, is reported to occur in about 
40–80% of relevant cases and typically leaves microscopic 
tumor fragments that are below the resolution of imaging 
examinations (Figs. 5, 6) (78, 79). Consequently, if patients 
without visible residual tumor on MRI after CRT for rectal 
cancer are offered the watch-and-wait management, a 
careful regular surveillance for tumor regrowth is crucial.
Interpretation of Complete Tumor Response on T2
A noteworthy finding is the somewhat heterogeneous 
criteria adopted by studies to diagnose complete tumor 
response on T2. Despite mild diversity, most of them have 
the commonality of a remarkable decrease of the tumor to 
the absence of mass-like or nodular intermediate signals 
(which would be perceived on T2 as residual tumor areas) 
in the tumor bed. Post-CRT changes in rectal cancer, as 
seen on T2, as well as pathologically are more complex 
than the simple characterization of normalization, fibrosis 
(hypointense signal on T2), and residual tumor (intermediate 
signal on T2) (8, 80). Complete normalization of the 
wall on MRI in the former tumor location is rare (8). 
Additionally, post-CRT changes without a residual tumor 
tissue can create an intermediate signal that can mimic the 
intermediate signal of a residual tumor (80). Therefore, the 
heterogeneous criteria adopted by the published studies 
list the varied T2 appearances of post-CRT state without 
apparent residual cancer (Fig. 7, Supplementary Materials). 
The findings of (near) normalization of the wall and regular, 
thin, hypointense scaring in the luminal side with (near) 
Table 3. Criteria for MRI Diagnosis of Complete Tumor Response
MR Method Criterion Number of Articles*
T2 Visible tumor signal is absent.
-  Normalization of wall in tumor bed; no detectable mass, nodular intermediate signal, or wall 
thickening (with individual layers of wall identified again)
4
-  mrTRG1†: linear/crescentic thin scar in mucosa/submucosa or apparent normalization of wall in  
tumor bed
5
-  Regular, hypointense scar in inner layer without bulging or breach by intermediate signal and  
homogeneous intermediate signal in underlying layer of wall in tumor bed
1
- Normalization of wall or hypointense wall (with thickening) without intermediate signal in tumor bed 5
- mrTRG1–2†: mrTRG1 or dense fibrosis with no obvious residual tumor 4
Visible tumor signal may be present in small amount.
- mrTRG1–3†: mrTRG1–2 or > 50% fibrosis or mucin and visible residual intermediate tumor signal 1
- Residual intermediate tumor signal in ≤ 25% of tumor bed 1
Obscure 3
DWI No hyperintense signal on high b-value (≥ 800 sec/mm2) DWI in tumor bed 8
Hyperintense signal in ≤ 25% in tumor bed 1
Obscure 2
Combined  
   T2 and  
DWI‡
When both T2 and DWI are negative for residual tumor 1
When both T2 and DWI are negative for residual tumor, with DWI being decisive if T2 findings are  
  equivocal
2
T2 findings as primary results, with DWI to override T2 when T2 findings are equivocal or DWI to increase 
  reader confidence if T2 and DWI findings are consistent
1
Obscure 4
*One article may present more than one criterion, †mrTRG is magnetic resonance tumor regression grade system proposed by MERCURY 
study group (24). Descriptions for mrTRG categories are according to most recent relevant papers (9, 24, 29), ‡Rules to combine T2 and 
DWI results.
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false interpretations for T2 shine-through effects, a signal 
from a different location than the former tumor site, and 
artefactual signals from susceptibility artifacts (8, 82).
Combining T2 and DWI
Published studies suggest that combined use of T2 
and DWI is better than using T2 alone to diagnose pCR. 
Nonetheless, the exact algorithm to combine the results of 
T2 and DWI was a bit obscure. If one places more emphasis 
on the oncologic outcome of the patients, it is reasonable 
to use DWI to exclude patients suspicious of remaining 
tumor after it was initially ruled out on T2. However, it is 
yet uncertain if a simple intersection of the two results in 
this manner, i.e., complete tumor response on MRI when 
both T2 and DWI are negative for residual tumor, is ideal 
as it would increase the specificity probably at the cost 
of some decrease in sensitivity for pCR (i.e., increased 
likelihood of sending patients with pCR for radical surgery). 
The studies that reported both increased sensitivity and 
normal-appearance or homogeneous intermediate signal 
in the underlying wall are reported to be less likely to 
harbor occult residual cancer compared to the finding of 
hypointense thickening of the wall (39, 81). Considering 
these factors, it would be desirable for the clinical reading 
of a post-CRT MRI to describe not only the absence vs. 
presence of visible residual tumor but also the specifics of 
the MRI findings interpreted as the lack of visible residual 
tumor.
Interpretation of Complete Tumor Response on DWI
The interpretation of complete tumor response on DWI 
was more uniform in the published studies as the absence 
of a hyperintense signal on high b-value DWI in the former 
tumor location. Nevertheless, the lack of anatomical 
details and the greater vulnerability to artifacts of DWI can 
introduce inaccuracy and variability in interpreting DWI 
according to the level of experience of the readers (8, 82). 
The readers should be particularly careful to avoid making 
Table 4. Studies Reporting Sensitivity and Specificity for Diagnosing pCR both for MRI Alone and for MRI Combined with Other 
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increased specificity for diagnosing pCR with the addition of 
DWI suggest that improved diagnostic performance without 
sacrificing any of both parameters is achievable (31, 34, 
40), likely by combining the two results in some obscure 
tailored manners. Therefore, further studies are needed to 
explicitly determine the optimal algorithms to combine 
T2 and DWI. Hence, all readers can use the two imaging 
methods together more reliably and more effectively.
Combining MRI and other Tests
One approach to deal with the limited accuracy of MRI 
in diagnosing pCR would be to combine it with other tests. 
This systematic review shows that the combination of MRI 
and endoscopy is the approach that is most favored by the 
experts in the field. This is consistent with the statistics 
collected by the International Watch and Wait Database 
Consortium from 47 participating institutions in 15 
countries (7). Published studies show that false diagnosis 
of pCR in patients who had a residual tumor could be 
reduced by combining MRI with other tests. However, it was 
at the cost of reduced sensitivity for pCR. These results are 
expected with the approach of deciding a complete tumor 
response if both MRI and other tests are all negative for 
the residual tumor. This approach would be appropriate if 
Table 5. Tests Used to Select Patients for Watch-and-Wait Management
First Author (Year) Article Type
Test Used* (+ = Used)
MRI Endoscopy EUS CT CEA PET EUA
Habr-Gama (1998) (50) Original research + + + +
Lambregts (2011) (59) Original research + + +
Maas (2011) (62) Original research + +
Dalton (2012) (48) Original research + +
Habr-Gama (2013) (52) Original research + + + +
Habr-Gama (2014) (51) Original research + + + +
Li (2015) (60) Original research + + + +
Smith (2015) (71) Original research + + +
Lai (2016) (58) Original research + + + +
Martens (2016) (63) Original research + +
Renehan (2016) (6) Original research + +
Rupinski (2016) (67) Original research + +
Sanchez Loria (2016) (68) Original research + +
Habr-Gama (2017) (54) Original research + +
Hupkens (2017) (57) Original research + +
Hupkens (2018) (56) Original research + +
Lin (2018) (61) Original research + + + +
Oh (2018) (65) Original research + + + + + +
São Julião (2018) (69) Original research + + + +
Sposato (2018) (74) Original research + +
Habr-Gama (2019) (53) Original research + +
Habr-Gama (2019) (55) Original research + + + + +
Nasir (2019) (64) Original research + +
São Julião (2019) (70) Original research + + + +
Smith (2019) (72) Original research +
Spiegel (2019) (73) Original research + + +
Strode (2019) (75) Original research + + + +
Yeom (2019) (76) Original research +
Dizdarevic (2020) (49) Original research + +
Barina (2017) (46) Study protocol† + + + +
Battersby (2017) (47) Study protocol† +
Rombouts (2017) (66) Study protocol† + +
*Evaluations that belong to basic physician assessment and physical examination such as digital rectal examination are not included. PET 
includes PET, PET-CT, and PET-MR, †Corresponding research results have not been published yet. CEA = carcinoembryonic antigen, EUA = 
examination under anesthesia, EUS = endorectal ultrasound
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complete tumor response on MRI with respect to the 
primary tumor, the entire clinical decision of complete 
tumor response requires the same evaluation for nodal 
metastasis and tumor deposits. To our knowledge, there 
is not enough data in the literature to draw an evidence 
synthesis on the evaluation for nodal metastasis and tumor 
deposits. Nevertheless, ESGAR has recently proposed as an 
expert consensus opinion that all nodes with a short-axis 
diameter < 5 mm and ≥ 5 mm on post-CRT MRI should be 
considered benign and suspicious, respectively (16). 
Summary
This systematic review and meta-analysis provide an 
oncologic outcome and safety are the concern. However, 
compared with the use of a single test, this approach would 
deprive an opportunity for less invasive management in 
more patients who have achieved pCR. There are yet limited 
data to confirm if and how a multi-test approach could 
increase the performance for diagnosing pCR and avoid 
sacrificing the sensitivity or the specificity. Therefore, 
further investigations are needed to determine the most 
effective strategy to combine different tests to select 
patients for the watch-and-wait management.
Issues Uncovered





Fig. 5. Microscopic size of residual tumor in case of near total 
regression after CRT for rectal cancer. Tiny nests of residual cancer 
cells are marked by arrowheads in most magnified (x 400) view. H&E 
stain (Courtesy of Dr. Hee Sang Hwang in Department of Pathology, Asan 
Medical Center, University of Ulsan College of Medicine, Seoul, Korea). 




Fig. 6. Microscopic size of residual tumor in case of moderate regression after CRT for rectal cancer.
A. Small glands of residual cancer cells are noted in tumor bed. H&E stain (Courtesy of Dr. Hee Sang Hwang in Department of Pathology, Asan 
Medical Center, University of Ulsan College of Medicine, Seoul, Korea). B. Residual tumor is still too small to be seen on MRI, albeit larger than 










Fig. 4. Schematic representation of patterns of rectal cancer 
response to CRT. Fragmentation is destruction of main tumor mass 
and formation of small nests of tumor cells, whereas shrinkage is 




evidence-based practical guide for MRI assessment of 
complete tumor response after CRT for rectal cancer. 
Within the limitation of considerable heterogeneity in the 
published results, with visual assessment, combined T2 and 
DWI seems more favorable than T2 alone in diagnosing pCR 
after CRT for rectal cancer and showed modest summary 
sensitivity and moderately high summary specificity. The 
criteria for complete tumor response on T2 may include 
(near) normalization of the wall; regular, thin, hypointense 
scar in the luminal side with (near) normal-appearance or 
homogeneous intermediate signal in the underlying wall; 
and hypointense thickening of the wall in the former tumor 
location. The criterion for complete tumor response on DWI 
should be the absence of a hyperintense signal on high 
b-value DWI in the former tumor location. The optimal 
algorithms to combine the results of T2 and DWI have yet 
to be defined more explicitly. The use of MRI and endoscopy 
was the most utilized means to select patients for the 
watch-and-wait management. However, the evidence is yet 
scarce regarding if a multi-test approach is beneficial and 
what combinations of the tests are most effective. 
Supplementary Materials
The Data Supplement is available with this article at 
https://doi.org/10.3348/kjr.2020.0483.
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Fig. 7. Exemplary cases of complete tumor response, i.e., no visible residual tumor on T2 after CRT.
A. Complete normalization of wall in tumor bed (arrowheads) after CRT. Pathology was total regression. B. Regular, thin, hypointense scar 
in luminal side and normalization of underlying wall in tumor bed (arrowheads) after CRT. Pathology was total regression. C. Regular, thin, 
hypointense scar in luminal side and a homogeneous, intermediate signal of underlying wall with mild thickening in tumor bed (arrowheads) 
after CRT. Pathology was total regression. D. Dense, hypointense thickening of wall in tumor bed (arrowheads) after CRT. Pathology was total 
regression.
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